English

Spruce Biosciences, Inc.

EDGAR

SPRB Quarterly report (10-Q) · filed 2026-08-12

Annual consolidated revenue for 2025: about USD 0, using the latest reported figures. The previous period, 2024, was about USD 4.9M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2025 Q4 · USD

Exact inputs and evidence

Revenue: 0 USD Source
Revenue: 0 USD Source

Operating cash flow

-6.46 million USD

2025 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -33327000 USD Source
Operating Cash Flow: -26871000 USD Source

Cash and cash equivalents: 96.3 million USD 2026-06-30 Source
Exact value

96295000 USD
Long-term debt including current maturities: 19.9 million USD 2026-06-30 Source
Exact value

19944000 USD
Shares outstanding: 2.75 million shares 2026-06-30 Source
Exact value

2752810 shares

Reported share-count change

388.92% · 2.19 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

563042 shares · 2025-06-30· Source
2752810 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

0 USD

2025-01-01 – 2025-12-31

Exact inputs and evidence

Revenue: 0 USD · 2025-01-01 – 2025-03-31 Source
Revenue: 0 USD · 2025-04-01 – 2025-06-30 Source
Revenue: 0 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 0 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 0 USD · 2025-01-01 – 2025-09-30 Source

Net income

-51.4 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -8212000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -38966000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -24320000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -12266000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -16229000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-42.6 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -26871000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -21555000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -33327000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -26871000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -8732000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -30852000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -8732000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-12.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 4 of 11 periods available· newest 2025-12-31
Operating income: 7 of 11 periods available· newest 2025-12-31
Net income: 7 of 11 periods available· newest 2025-12-31
Operating cash flow: 7 of 11 periods available· newest 2025-12-31
Capital expenditure: 6 of 11 periods available· newest 2024-12-31
Total assets: 4 of 11 periods available· newest 2025-12-31
Total liabilities: 4 of 11 periods available· newest 2025-12-31
Current assets: 4 of 11 periods available· newest 2025-12-31
Current liabilities: 4 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 4 of 11 periods available· newest 2025-12-31
Long-term debt including current maturities: 3 of 11 periods available· newest 2024-12-31
Shares outstanding: 4 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-100%

Prior period

USD 4.9 million

2024-01-01 – 2024-12-31
Current period

USD 0

2025-01-01 – 2025-12-31

Exact inputs and evidence

0 − 4900000 = -4900000 USD

4900000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
0 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Spruce Biosciences, Inc. · 2025-12-31 Spruce Biosciences, Inc. (edgar:1683553) Year-over-year change in Revenue: -4900000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1683553?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 0 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1683553/000119312526097558/sprb-20251231.htm#1464549 Filing: 000119312526097558 Input fundies:Revenue: 4900000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1683553/000119312526097558/sprb-20251231.htm#2155074 Filing: 000119312526097558
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 14.07 million

Prior period

−USD 53.04 million

2024-01-01 – 2024-12-31
Current period

−USD 38.97 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-38966000 − -53036000 = 14070000 USD

-53036000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-38966000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Spruce Biosciences, Inc. · 2025-12-31 Spruce Biosciences, Inc. (edgar:1683553) Year-over-year change in Net income: 14070000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1683553?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -38966000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1683553/000119312526097558/sprb-20251231.htm#2572348 Filing: 000119312526097558 Input fundies:NetIncome: -53036000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1683553/000119312526097558/sprb-20251231.htm#2574095 Filing: 000119312526097558
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 22.64 million

Prior period

−USD 55.96 million

2024-01-01 – 2024-12-31
Current period

−USD 33.33 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-33327000 − -55964000 = 22637000 USD

-55964000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-33327000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Spruce Biosciences, Inc. · 2025-12-31 Spruce Biosciences, Inc. (edgar:1683553) Year-over-year change in Operating cash flow: 22637000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1683553?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -33327000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1683553/000119312526097558/sprb-20251231.htm#1719905 Filing: 000119312526097558 Input fundies:OperatingCashFlow: -55964000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1683553/000119312526097558/sprb-20251231.htm#1721760 Filing: 000119312526097558
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 0
Operating costs Derived USD 36.51 million
Operating income −USD 36.51 million
Tax, interest and other Derived USD 2.45 million
Net income −USD 38.97 million

Cash

Operating cash flow −USD 33.33 million
Capital expenditure Unavailable An input is unavailable.
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2022 Not shown: operating income or net income is not reported.
2023 Operating loss: operating costs were 615% of revenue.
2024 Operating loss: operating costs were 1,246% of revenue.
2025 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2022 2022-01-01 – 2022-12-31	0	47283000 Derived	-47283000	-1103000 Derived	-46180000	-41691000 Derived	Source 2022-01-01 – 2022-12-31: 0 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -47283000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -46180000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -41683000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 8000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	10100000	62093000 Derived	-51993000	-4074000 Derived	-47919000	-33282000 Derived	Source 2023-01-01 – 2023-12-31: 10100000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -51993000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -47919000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -33275000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 7000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	4900000	61051000 Derived	-56151000	-3115000 Derived	-53036000	-55964000 Derived	Source 2024-01-01 – 2024-12-31: 4900000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -56151000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -53036000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -55964000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 0 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	0	36513000 Derived	-36513000	2453000 Derived	-38966000	Unavailable	Source 2025-01-01 – 2025-12-31: 0 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -36513000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -38966000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -33327000 USD Inspect Operating Cash Flow Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 0 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20222022-12-31	Revenue	0	Revenue: 0 Open source
20232023-12-31	Revenue	10100000	Revenue: 10100000 Open source
20242024-12-31	Revenue	4900000	Revenue: 4900000 Open source
20252025-12-31	Revenue	0	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-100% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20222022-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20232023-12-31	Year over year	No prior comparable period	Revenue: 10100000 Open source Revenue: 0 Open source
20242024-12-31	Year over year	-51.5%	Revenue: 4900000 Open source Revenue: 10100000 Open source
20252025-12-31	Year over year	-100%	Revenue: 0 Open source Revenue: 4900000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -1,145.9% 2024

Net margin -1,082.4% 2024

Free cash flow margin -1,142.1% 2024

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20222022-12-31	Operating margin	Not reported	Operating Income: -47283000 Open source Revenue: 0 Open source
20232023-12-31	Operating margin	-514.8%	Operating Income: -51993000 Open source Revenue: 10100000 Open source
20242024-12-31	Operating margin	-1,145.9%	Operating Income: -56151000 Open source Revenue: 4900000 Open source
20252025-12-31	Operating margin	Not reported	Operating Income: -36513000 Open source Revenue: 0 Open source
20222022-12-31	Net margin	Not reported	Net Income: -46180000 Open source Revenue: 0 Open source
20232023-12-31	Net margin	-474.4%	Net Income: -47919000 Open source Revenue: 10100000 Open source
20242024-12-31	Net margin	-1,082.4%	Net Income: -53036000 Open source Revenue: 4900000 Open source
20252025-12-31	Net margin	Not reported	Net Income: -38966000 Open source Revenue: 0 Open source
20222022-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -41683000 Open source Capital Expenditure: 8000 Open source
20232023-12-31	Free cash flow margin	-329.5%	Revenue: 10100000 Open source Operating Cash Flow: -33275000 Open source Capital Expenditure: 7000 Open source
20242024-12-31	Free cash flow margin	-1,142.1%	Revenue: 4900000 Open source Operating Cash Flow: -55964000 Open source Capital Expenditure: 0 Open source
20252025-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -33327000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -33.3M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20222022-12-31	Operating cash flow	-41683000	Operating Cash Flow: -41683000 Open source
20232023-12-31	Operating cash flow	-33275000	Operating Cash Flow: -33275000 Open source
20242024-12-31	Operating cash flow	-55964000	Operating Cash Flow: -55964000 Open source
20252025-12-31	Operating cash flow	-33327000	Operating Cash Flow: -33327000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -56M 2024

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20222022-12-31	Free cash flow	-41691000	Operating Cash Flow: -41683000 Open source Capital Expenditure: 8000 Open source
20232023-12-31	Free cash flow	-33282000	Operating Cash Flow: -33275000 Open source Capital Expenditure: 7000 Open source
20242024-12-31	Free cash flow	-55964000	Operating Cash Flow: -55964000 Open source Capital Expenditure: 0 Open source
20252025-12-31	Free cash flow	Unavailable	Operating Cash Flow: -33327000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

19.8% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20222022-12-31	Liabilities / assets	20%	Total Liabilities: 17162000 Open source Total Assets: 85648000 Open source
20232023-12-31	Liabilities / assets	26.4%	Total Liabilities: 27437000 Open source Total Assets: 103946000 Open source
20242024-12-31	Liabilities / assets	36.2%	Total Liabilities: 16388000 Open source Total Assets: 45209000 Open source
20252025-12-31	Liabilities / assets	19.8%	Total Liabilities: 10505000 Open source Total Assets: 53021000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

5.17× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20222022-12-31	Current assets / current liabilities	6.72×	Current Assets: 83608000 Open source Current Liabilities: 12447000 Open source
20232023-12-31	Current assets / current liabilities	4.18×	Current Assets: 102183000 Open source Current Liabilities: 24465000 Open source
20242024-12-31	Current assets / current liabilities	2.9×	Current Assets: 44206000 Open source Current Liabilities: 15246000 Open source
20252025-12-31	Current assets / current liabilities	5.17×	Current Assets: 52112000 Open source Current Liabilities: 10086000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2019 2019-01-01 – 2019-12-31	−USD 13.09 million Exact value Exact value: -13088000 USD 2019-01-01 – 2019-12-31: -13088000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Spruce Biosciences, Inc. · 2019-12-31 Spruce Biosciences, Inc. (edgar:1683553) Net Income: -13088000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1683553/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -13088000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1683553/000156459021014593/sprb-20201231.xml#112716 Filing: 000156459021014593 The citation records this snapshot. The page link may show a newer release later.	−USD 12.62 million Exact value Exact value: -12617000 USD 2019-01-01 – 2019-12-31: -12617000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Spruce Biosciences, Inc. · 2019-12-31 Spruce Biosciences, Inc. (edgar:1683553) Operating Cash Flow: -12617000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1683553/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -12617000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1683553/000156459021014593/sprb-20201231.xml#129842 Filing: 000156459021014593 The citation records this snapshot. The page link may show a newer release later.	USD 4,000 Exact value Exact value: 4000 USD 2019-01-01 – 2019-12-31: 4000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Spruce Biosciences, Inc. · 2019-12-31 Spruce Biosciences, Inc. (edgar:1683553) Capital Expenditure: 4000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1683553/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1683553/000156459021014593/sprb-20201231.xml#130262 Filing: 000156459021014593 The citation records this snapshot. The page link may show a newer release later.	−USD 12.62 million Calculation and evidence -12617000 − 4000 USD Exact free cash flow: -12621000 USD 2019-01-01 – 2019-12-31: -12617000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 4000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Spruce Biosciences, Inc. · 2019-12-31 Spruce Biosciences, Inc. (edgar:1683553) Free cash flow: -12621000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1683553?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -12617000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1683553/000156459021014593/sprb-20201231.xml#129842 Filing: 000156459021014593 Input fundies:CapitalExpenditure: 4000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1683553/000156459021014593/sprb-20201231.xml#130262 Filing: 000156459021014593 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 29.54 million Exact value Exact value: -29539000 USD 2020-01-01 – 2020-12-31: -29539000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Spruce Biosciences, Inc. · 2020-12-31 Spruce Biosciences, Inc. (edgar:1683553) Net Income: -29539000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1683553/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -29539000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1683553/000095017022003582/sprb-20211231.htm#3116980 Filing: 000095017022003582 The citation records this snapshot. The page link may show a newer release later.	−USD 27.52 million Exact value Exact value: -27519000 USD 2020-01-01 – 2020-12-31: -27519000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Spruce Biosciences, Inc. · 2020-12-31 Spruce Biosciences, Inc. (edgar:1683553) Operating Cash Flow: -27519000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1683553/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -27519000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1683553/000095017022003582/sprb-20211231.htm#2073110 Filing: 000095017022003582 The citation records this snapshot. The page link may show a newer release later.	USD 74,000 Exact value Exact value: 74000 USD 2020-01-01 – 2020-12-31: 74000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Spruce Biosciences, Inc. · 2020-12-31 Spruce Biosciences, Inc. (edgar:1683553) Capital Expenditure: 74000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1683553/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 74000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1683553/000095017022003582/sprb-20211231.htm#2080297 Filing: 000095017022003582 The citation records this snapshot. The page link may show a newer release later.	−USD 27.59 million Calculation and evidence -27519000 − 74000 USD Exact free cash flow: -27593000 USD 2020-01-01 – 2020-12-31: -27519000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 74000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Spruce Biosciences, Inc. · 2020-12-31 Spruce Biosciences, Inc. (edgar:1683553) Free cash flow: -27593000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1683553?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -27519000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1683553/000095017022003582/sprb-20211231.htm#2073110 Filing: 000095017022003582 Input fundies:CapitalExpenditure: 74000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1683553/000095017022003582/sprb-20211231.htm#2080297 Filing: 000095017022003582 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 42.29 million Exact value Exact value: -42292000 USD 2021-01-01 – 2021-12-31: -42292000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Spruce Biosciences, Inc. · 2021-12-31 Spruce Biosciences, Inc. (edgar:1683553) Net Income: -42292000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1683553/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -42292000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1683553/000095017023008456/sprb-20221231.htm#3151342 Filing: 000095017023008456 The citation records this snapshot. The page link may show a newer release later.	−USD 35.88 million Exact value Exact value: -35877000 USD 2021-01-01 – 2021-12-31: -35877000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Spruce Biosciences, Inc. · 2021-12-31 Spruce Biosciences, Inc. (edgar:1683553) Operating Cash Flow: -35877000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1683553/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -35877000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1683553/000095017023008456/sprb-20221231.htm#2067214 Filing: 000095017023008456 The citation records this snapshot. The page link may show a newer release later.	USD 93,000 Exact value Exact value: 93000 USD 2021-01-01 – 2021-12-31: 93000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Spruce Biosciences, Inc. · 2021-12-31 Spruce Biosciences, Inc. (edgar:1683553) Capital Expenditure: 93000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1683553/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 93000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1683553/000095017023008456/sprb-20221231.htm#2084767 Filing: 000095017023008456 The citation records this snapshot. The page link may show a newer release later.	−USD 35.97 million Calculation and evidence -35877000 − 93000 USD Exact free cash flow: -35970000 USD 2021-01-01 – 2021-12-31: -35877000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 93000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Spruce Biosciences, Inc. · 2021-12-31 Spruce Biosciences, Inc. (edgar:1683553) Free cash flow: -35970000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1683553?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -35877000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1683553/000095017023008456/sprb-20221231.htm#2067214 Filing: 000095017023008456 Input fundies:CapitalExpenditure: 93000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1683553/000095017023008456/sprb-20221231.htm#2084767 Filing: 000095017023008456 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 46.18 million Exact value Exact value: -46180000 USD 2022-01-01 – 2022-12-31: -46180000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Spruce Biosciences, Inc. · 2022-12-31 Spruce Biosciences, Inc. (edgar:1683553) Net Income: -46180000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1683553/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -46180000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1683553/000095017024032819/sprb-20231231.htm#2373043 Filing: 000095017024032819 The citation records this snapshot. The page link may show a newer release later.	−USD 41.68 million Exact value Exact value: -41683000 USD 2022-01-01 – 2022-12-31: -41683000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Spruce Biosciences, Inc. · 2022-12-31 Spruce Biosciences, Inc. (edgar:1683553) Operating Cash Flow: -41683000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1683553/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -41683000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1683553/000095017024032819/sprb-20231231.htm#1653849 Filing: 000095017024032819 The citation records this snapshot. The page link may show a newer release later.	USD 8,000 Exact value Exact value: 8000 USD 2022-01-01 – 2022-12-31: 8000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Spruce Biosciences, Inc. · 2022-12-31 Spruce Biosciences, Inc. (edgar:1683553) Capital Expenditure: 8000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1683553/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 8000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1683553/000095017024032819/sprb-20231231.htm#1664688 Filing: 000095017024032819 The citation records this snapshot. The page link may show a newer release later.	−USD 41.69 million Calculation and evidence -41683000 − 8000 USD Exact free cash flow: -41691000 USD 2022-01-01 – 2022-12-31: -41683000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 8000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Spruce Biosciences, Inc. · 2022-12-31 Spruce Biosciences, Inc. (edgar:1683553) Free cash flow: -41691000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1683553?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -41683000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1683553/000095017024032819/sprb-20231231.htm#1653849 Filing: 000095017024032819 Input fundies:CapitalExpenditure: 8000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1683553/000095017024032819/sprb-20231231.htm#1664688 Filing: 000095017024032819 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 47.92 million Exact value Exact value: -47919000 USD 2023-01-01 – 2023-12-31: -47919000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Spruce Biosciences, Inc. · 2023-12-31 Spruce Biosciences, Inc. (edgar:1683553) Net Income: -47919000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1683553/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -47919000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1683553/000095017025053945/sprb-20241231.htm#2483274 Filing: 000095017025053945 The citation records this snapshot. The page link may show a newer release later.	−USD 33.28 million Exact value Exact value: -33275000 USD 2023-01-01 – 2023-12-31: -33275000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Spruce Biosciences, Inc. · 2023-12-31 Spruce Biosciences, Inc. (edgar:1683553) Operating Cash Flow: -33275000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1683553/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -33275000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1683553/000095017025053945/sprb-20241231.htm#1710404 Filing: 000095017025053945 The citation records this snapshot. The page link may show a newer release later.	USD 7,000 Exact value Exact value: 7000 USD 2023-01-01 – 2023-12-31: 7000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Spruce Biosciences, Inc. · 2023-12-31 Spruce Biosciences, Inc. (edgar:1683553) Capital Expenditure: 7000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1683553/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 7000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1683553/000095017025053945/sprb-20241231.htm#1723754 Filing: 000095017025053945 The citation records this snapshot. The page link may show a newer release later.	−USD 33.28 million Calculation and evidence -33275000 − 7000 USD Exact free cash flow: -33282000 USD 2023-01-01 – 2023-12-31: -33275000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 7000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Spruce Biosciences, Inc. · 2023-12-31 Spruce Biosciences, Inc. (edgar:1683553) Free cash flow: -33282000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1683553?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -33275000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1683553/000095017025053945/sprb-20241231.htm#1710404 Filing: 000095017025053945 Input fundies:CapitalExpenditure: 7000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1683553/000095017025053945/sprb-20241231.htm#1723754 Filing: 000095017025053945 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 53.04 million Exact value Exact value: -53036000 USD 2024-01-01 – 2024-12-31: -53036000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Spruce Biosciences, Inc. · 2024-12-31 Spruce Biosciences, Inc. (edgar:1683553) Net Income: -53036000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1683553/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -53036000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1683553/000119312526097558/sprb-20251231.htm#2574095 Filing: 000119312526097558 The citation records this snapshot. The page link may show a newer release later.	−USD 55.96 million Exact value Exact value: -55964000 USD 2024-01-01 – 2024-12-31: -55964000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Spruce Biosciences, Inc. · 2024-12-31 Spruce Biosciences, Inc. (edgar:1683553) Operating Cash Flow: -55964000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1683553/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -55964000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1683553/000119312526097558/sprb-20251231.htm#1721760 Filing: 000119312526097558 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2024-01-01 – 2024-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Spruce Biosciences, Inc. · 2024-12-31 Spruce Biosciences, Inc. (edgar:1683553) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1683553/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1683553/000095017025053945/sprb-20241231.htm#1722037 Filing: 000095017025053945 The citation records this snapshot. The page link may show a newer release later.	−USD 55.96 million Calculation and evidence -55964000 − 0 USD Exact free cash flow: -55964000 USD 2024-01-01 – 2024-12-31: -55964000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Spruce Biosciences, Inc. · 2024-12-31 Spruce Biosciences, Inc. (edgar:1683553) Free cash flow: -55964000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1683553?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -55964000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1683553/000119312526097558/sprb-20251231.htm#1721760 Filing: 000119312526097558 Input fundies:CapitalExpenditure: 0 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1683553/000095017025053945/sprb-20241231.htm#1722037 Filing: 000095017025053945 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 38.97 million Exact value Exact value: -38966000 USD 2025-01-01 – 2025-12-31: -38966000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Spruce Biosciences, Inc. · 2025-12-31 Spruce Biosciences, Inc. (edgar:1683553) Net Income: -38966000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1683553/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -38966000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1683553/000119312526097558/sprb-20251231.htm#2572348 Filing: 000119312526097558 The citation records this snapshot. The page link may show a newer release later.	−USD 33.33 million Exact value Exact value: -33327000 USD 2025-01-01 – 2025-12-31: -33327000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Spruce Biosciences, Inc. · 2025-12-31 Spruce Biosciences, Inc. (edgar:1683553) Operating Cash Flow: -33327000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1683553/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -33327000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1683553/000119312526097558/sprb-20251231.htm#1719905 Filing: 000119312526097558 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

31 filings · 1,605 latest values · 1,605 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001683553, 1683553, SPRB, SPRBD, edgar:1683553

Also known as SPRUCE BIOSCIENCES, INC., Spruce Biosciences, Inc.

Spruce Biosciences, Inc.

Latest quarter

Revenue

Operating cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation